Option chain shows key data for Alliance Growers's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for Alliance Growers.

Alliance Growers (OTC:ALGWF) Stock, Option Chain

Alliance Growers Corp is a Canada based diversified cannabis company. It principally operates through the four key divisions namely, Cannabis Botany Centre, Strategic Access to Cannabis for Medical Purposes Regulations Investments, Cannabidiol Oil Supply and Distribution, and Research and Development. The company is focused on the development of Cannabis Botany Centres in Canada.

News

Movers & Shakers

Intraday Update

Markets

Movers

Trading Ideas

General

ABNAF

ACRX

ADGO

AJXGF

ALGWF

AMPH

ANDR

AREX

ASCK

ASRT

BCRX

BVTK

CANL

CDXC

CHKDG

CHMJF

CHOOF

CNBX

COCP

CTRA

CTRC

DFFN

DMAN

DOGZ

DPLO

ENBL

ESEA

ESVIF

ETRN

ETSY

EXPE

EZPW

FAMI

FBEC

FFLWF

FLNT

FNRC

FOSL

FRRSF

FTSI

GBLX

GELT

GLOG

HGTXU

HQGE

HSDT

ICNAF

IDEX

INPX

IONKF

JKSM

JROOF

KGJI

MDCN

MENEF

MGTI

MITK

MPLX

NLBIF

NRGMF

NSCO

NTWK

ONTX

ORMP

OSTK

OTTV

OZSC

PACXF

PAGP

PDSB

PRMW

QUIK

RIOFF

RVLV

SDRL

SEEL

SLDB

SWIR

TIGO

TRLFF

TRPX

TUSK

UNIT

Stocks That Hit 52-Week Lows On Tuesday

ALLIANCE GROWERS CORP by Alliance Growers Corp

Alliance Growers Corp

HC Wainwright &amp; Co. analyst Vernon Bernardino reiterates Cardiol Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRDL#NASDAQ">CRDL</a>) with a Buy and maintains $9 price target.

Price Target

Reiteration

Analyst Ratings

CRDL

HC Wainwright & Co. Reiterates Buy on Cardiol Therapeutics, Maintains $9 Price Target

Barclays analyst Eddie Kim downgrades Valaris (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VAL#NYSE">VAL</a>) from Overweight to Equal-Weight and lowers the price target from $59 to $49.

Downgrades

Barclays Downgrades Valaris to Equal-Weight, Lowers Price Target to $49

HC Wainwright &amp; Co. analyst Vernon Bernardino reiterates Candel Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CADL#NASDAQ">CADL</a>) with a Buy and raises the price target from $11 to $19.

CADL

HC Wainwright & Co. Reiterates Buy on Candel Therapeutics, Raises Price Target to $19

BTCM

BIT Mining Receives NYSE Letter That It Regained Compliance With Quantitative Continued Listing Standards

HC Wainwright &amp; Co. analyst Joseph Pantginis reiterates Krystal Biotech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KRYS#NASDAQ">KRYS</a>) with a Buy and maintains $221 price target.

KRYS

HC Wainwright & Co. Reiterates Buy on Krystal Biotech, Maintains $221 Price Target

Barclays analyst David Anderson downgrades Halliburton (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HAL#NYSE">HAL</a>) from Overweight to Equal-Weight and lowers the price target from $43 to $33.

Barclays Downgrades Halliburton to Equal-Weight, Lowers Price Target to $33

Under the agreement, Hansoh Pharma has granted Merck an exclusive global license to develop, manufacture and commercialize HS-10535. Hansoh Pharma will receive an upfront payment of $112 million and is eligible to receive up to $1.9 billion in milestone payments associated with the development, regulatory approval and commercialization of the candidate, as well as royalties on sales.
Hansoh Pharma may co-promote or solely commercialize HS-10535 in China subject to certain conditions. Merck will record a pre-tax charge of $112 million, or $0.04 per share, to be included in GAAP and non-GAAP results in the fourth quarter of 2024.

Merck, Hansoh Pharma Enter Exclusive Global License Agreement For HS-10535, An Investigational Preclinical Oral Small Molecule GLP-1 Receptor Agonist; Hansoh To Receive An Upfront Payment Of $112M And Up To $1.9B In Milestones

Needham analyst Laura Martin reiterates Taboola.com (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TBLA#NASDAQ">TBLA</a>) with a Buy and maintains $5 price target.

TBLA

Needham Reiterates Buy on Taboola.com, Maintains $5 Price Target

JP Morgan analyst Cory Carpenter maintains Take-Two Interactive (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TTWO#NASDAQ">TTWO</a>) with a Overweight and raises the price target from $195 to $225.

TTWO

JP Morgan Maintains Overweight on Take-Two Interactive, Raises Price Target to $225

HC Wainwright &amp; Co. analyst Joseph Pantginis reiterates PDS Biotechnology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PDSB#NASDAQ">PDSB</a>) with a Buy and maintains $21 price target.

HC Wainwright & Co. Reiterates Buy on PDS Biotechnology, Maintains $21 Price Target

JP Morgan analyst David Karnovsky downgrades PLAYSTUDIOS (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MYPS#NASDAQ">MYPS</a>) from Neutral to Underweight.

MYPS

JP Morgan Downgrades PLAYSTUDIOS to Underweight

Needham analyst Scott Berg reiterates Salesforce (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CRM#NYSE">CRM</a>) with a Buy and maintains $375 price target.

Needham Reiterates Buy on Salesforce, Maintains $375 Price Target

JP Morgan analyst Doug Anmuth downgrades Angi (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ANGI#NASDAQ">ANGI</a>) from Overweight to Neutral.

ANGI

JP Morgan Downgrades Angi to Neutral

UMC will purchase more than 30 billion kilowatt-hours of power from Fengmiao I over least 30 years.
&nbsp;This agreement will help UMC achieve its goal of 50% renewable energy use by 2030 as part of the company's roadmap to net zero emissions and 100% renewable energy by 2050.

United Microelectronics Inks 30-Year, 30B kWh Offshore Wind Power Agreement  With Fengmiao I

HC Wainwright &amp; Co. analyst Swayampakula Ramakanth reiterates ALX Oncology Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALXO#NASDAQ">ALXO</a>) with a Buy and maintains $25 price target.

ALXO

HC Wainwright & Co. Reiterates Buy on ALX Oncology Holdings, Maintains $25 Price Target

JP Morgan analyst Cory Carpenter downgrades Getty Images Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GETY#NYSE">GETY</a>) from Neutral to Underweight.

GETY

JP Morgan Downgrades Getty Images Holdings to Underweight

The engagement with an EU-based GMP manufacturing facility enables timely production and preparation for clinical trial. The EU-based GMP manufacturer has large-scale commercial production capabilities, to support Polyrizon in future commercialization efforts

PLRZ

Polyrizon Secures GMP Manufacturing Partnership With Eurofins CDMO Amatsiaquitaine, Advancing Toward PL-14 Allergy Blocker Clinical Trial In 2025

CMPS

Compass Pathways Common Stock To Be Added To The Nasdaq Biotechnology Index

JP Morgan analyst Cory Carpenter upgrades Xometry (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XMTR#NASDAQ">XMTR</a>) from Neutral to Overweight and raises the price target from $25 to $45.

Upgrades

XMTR

JP Morgan Upgrades Xometry to Overweight, Raises Price Target to $45

JP Morgan analyst Cory Carpenter downgrades Match Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MTCH#NASDAQ">MTCH</a>) from Overweight to Neutral and lowers the price target from $40 to $33.

MTCH

JP Morgan Downgrades Match Group to Neutral, Lowers Price Target to $33

Alliance Growers

Comments

Alliance Growers

Alliance Growers (ALGWF) Options

No option chain data available. Please try again later

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga